BriaCell Therapeutics Corp. (BCT.TO) TSX
4.51
-0.05(-1.10%)
Currency In CAD
- General
- Statistics
- Historical Data
- Profile
- Financials
4.51
-0.05(-1.10%)
Currency In CAD
Address
Bellevue Centre
West Vancouver, BC V7T 2X1
Canada
Phone
604-921-1810
Website
Sector
Healthcare
Industry
Biotechnology
Employees
16
First IPO Date
August 13, 2012
| Name | Title | Pay | Year Born |
| William V. Williams | Chief Executive Officer, President & Director | 982,606 | 1955 |
| Charles Louis Wiseman FACP | Founder, Principal Research Advisor & Member of Scientific Advisory Board | 332,915 | 1947 |
| Miguel A. Lopez-Lago | Chief Scientific Officer | 617,883 | 1970 |
| Giuseppe Del Priore | Chief Medical Officer | 680,702 | 1962 |
| Gadi Levin | Chief Financial Officer & Corporate Secretary | 739,119 | 1973 |
BriaCell Therapeutics Corp., an immuno-oncology-focused biotechnology company, engages in developing immunotherapies for the management of cancer. Its lead drug candidate is Bria-IMT, a whole-cell cancer vaccine that is in Phase I/IIa clinical trials in combination with the immunotherapy development candidates retifanlimab. The company is also developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test that determines the patients' HLA types. It has a non-exclusive clinical trial collaboration with Incyte Corporation to evaluate the effects of combinations of novel clinical candidates; and a cooperative research and development agreement with the National Cancer Institute to conduct preclinical studies to develop and test Bria-OTS cellular immunotherapy as a treatment for cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.